A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

Trial Details

NCT ID
NCT05954312
Phase
PHASE1
Sponsor
Vividion Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • VVD-130037
  • Docetaxel
  • Paclitaxel
  • Pembrolizumab
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Tampa, Florida, United States|27.94752,-82.45843
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic or unresectable solid tumor.
  • Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the Investigator.
  • Have progressed on or after all prior standard-of-care therapies for metastatic disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →